JP6712993B2 - 免疫細胞を惹起及び／又は活性化するための免疫応答刺激性サイトカインを発現する遺伝子改変型間葉系幹細胞 - Google Patents

免疫細胞を惹起及び／又は活性化するための免疫応答刺激性サイトカインを発現する遺伝子改変型間葉系幹細胞 Download PDF

Info

Publication number
JP6712993B2
JP6712993B2 JP2017509626A JP2017509626A JP6712993B2 JP 6712993 B2 JP6712993 B2 JP 6712993B2 JP 2017509626 A JP2017509626 A JP 2017509626A JP 2017509626 A JP2017509626 A JP 2017509626A JP 6712993 B2 JP6712993 B2 JP 6712993B2
Authority
JP
Japan
Prior art keywords
cells
tumor
cell
immune
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017509626A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525364A (ja
JP2017525364A5 (cg-RX-API-DMAC7.html
Inventor
ギュンター，クリスチーネ
テオハリス，ステファノ
ヘルマン，フェリクス
フス，ラルフ
Original Assignee
アプセト ゲーエムベーハー アンド ツェーオー．カーゲー
アプセト ゲーエムベーハー アンド ツェーオー．カーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アプセト ゲーエムベーハー アンド ツェーオー．カーゲー, アプセト ゲーエムベーハー アンド ツェーオー．カーゲー filed Critical アプセト ゲーエムベーハー アンド ツェーオー．カーゲー
Publication of JP2017525364A publication Critical patent/JP2017525364A/ja
Publication of JP2017525364A5 publication Critical patent/JP2017525364A5/ja
Application granted granted Critical
Publication of JP6712993B2 publication Critical patent/JP6712993B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017509626A 2014-08-18 2015-08-18 免疫細胞を惹起及び／又は活性化するための免疫応答刺激性サイトカインを発現する遺伝子改変型間葉系幹細胞 Active JP6712993B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14181283 2014-08-18
EP14181283.4 2014-08-18
PCT/EP2015/068942 WO2016026854A2 (en) 2014-08-18 2015-08-18 Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells

Publications (3)

Publication Number Publication Date
JP2017525364A JP2017525364A (ja) 2017-09-07
JP2017525364A5 JP2017525364A5 (cg-RX-API-DMAC7.html) 2018-09-20
JP6712993B2 true JP6712993B2 (ja) 2020-06-24

Family

ID=51352460

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017509626A Active JP6712993B2 (ja) 2014-08-18 2015-08-18 免疫細胞を惹起及び／又は活性化するための免疫応答刺激性サイトカインを発現する遺伝子改変型間葉系幹細胞

Country Status (8)

Country Link
US (2) US20170239297A1 (cg-RX-API-DMAC7.html)
EP (2) EP3182984B1 (cg-RX-API-DMAC7.html)
JP (1) JP6712993B2 (cg-RX-API-DMAC7.html)
CN (1) CN106659742B (cg-RX-API-DMAC7.html)
AU (1) AU2015306231B2 (cg-RX-API-DMAC7.html)
CA (1) CA2956987C (cg-RX-API-DMAC7.html)
IL (1) IL250388B (cg-RX-API-DMAC7.html)
WO (1) WO2016026854A2 (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
AU2015221181B2 (en) * 2014-02-19 2020-08-20 Merck Patent Gmbh Cancer-targeted IL-12 immunotherapy
CN108884440A (zh) 2016-04-01 2018-11-23 埃普塞斯有限责任两合公司 用于增强免疫疗法的抗肿瘤活性的间充质干细胞
WO2018071295A1 (en) * 2016-10-10 2018-04-19 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for inducible production of anti-inflammatory cytokines
CN108148862B (zh) 2016-12-05 2019-03-08 上海优卡迪生物医药科技有限公司 一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用
EP3595684A1 (en) * 2017-03-17 2020-01-22 Senti Biosciences, Inc. Immunomodulating cell circuits
WO2018184074A1 (en) * 2017-04-07 2018-10-11 Cynata Therapeutics Limited Method for treating a side effect of chimeric antigen receptor (car) t cell therapy
AU2018251898A1 (en) * 2017-04-13 2019-10-31 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CN107184603B (zh) * 2017-06-01 2020-06-30 刘未斌 一种治疗肿瘤的药物组合
CN107184602B (zh) * 2017-06-01 2020-06-30 刘未斌 一种治疗肿瘤的药物组合
SG11201912200YA (en) * 2017-06-16 2020-01-30 Cynata Therapeutics Ltd Method for treating a side effect of immunotherapy
WO2019067491A1 (en) * 2017-09-29 2019-04-04 Oncocyclist, Inc. COMPOSITION AND METHOD FOR TREATING CELL PROLIFERATION
US12016882B2 (en) 2017-11-22 2024-06-25 The Brigham And Women's Hospital, Inc. Method of treating glioblastoma multiforme
IL264068B2 (en) 2018-01-05 2023-07-01 Great Novel Therapeutics Biotech & Medicals Corp Aggregate and pharmaceutical preparation containing an hdac inhibitor and an nsaid aggregate together with an immune checkpoint inhibitor for use in a method for removing immunosuppression in the microenvironment of a tumor or stimulating an immune system against cancer cells
KR20200108316A (ko) * 2018-01-12 2020-09-17 루트거스, 더 스테이트 유니버시티 오브 뉴 저지 세포 리프로그래밍 요법
AU2019203918B2 (en) 2018-01-25 2020-04-30 I-Mab Biopharma Us Limited Anti-PD-L1 antibody and IL-7 fusions
EP3747459A4 (en) * 2018-02-02 2021-12-01 SL Vaxigen, Inc. NEW IMMUNOADJUVANT VACCINE
WO2019179400A1 (en) * 2018-03-21 2019-09-26 China Medical University Engineering stem cells for cancer therapy
CN108864288A (zh) * 2018-04-26 2018-11-23 上海怡豪生物科技有限公司 乳腺癌的双靶点car-t治疗载体及其构建方法和应用
CN110527696A (zh) * 2018-06-13 2019-12-03 中山大学 一种IFNβ和FerritinH基因联合修饰的骨髓间充质干细胞及其制备方法和应用
CN108815188A (zh) * 2018-07-06 2018-11-16 浙江生创精准医疗科技有限公司 包含间充质干细胞制剂与免疫检查点抑制剂的肿瘤治疗组合物、试剂盒及其用途
CN112384231A (zh) * 2018-08-26 2021-02-19 奥伊斯细胞生物技术公司 用于治疗胶质母细胞瘤的方法
US20220096544A1 (en) * 2018-09-20 2022-03-31 Cafa Therapeutics Limited Chemokine expressing cell and use thereof
CN113286874A (zh) * 2018-10-12 2021-08-20 美商生物细胞基因治疗有限公司 嵌合抗原受体(CARs)组合物及使用方法
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
JP2022512766A (ja) 2018-10-17 2022-02-07 センティ バイオサイエンシズ インコーポレイテッド 組み合わせがん免疫療法
CN109593725A (zh) * 2018-12-25 2019-04-09 河北生命原点生物科技有限公司 一种重组间充质干细胞及其应用
CN113795755A (zh) * 2019-02-14 2021-12-14 全国儿童医院研究所 质膜颗粒、脂质体和外泌体用于测定免疫细胞效力的用途
CN109762820B (zh) * 2019-02-18 2020-07-28 河北佑仁生物科技有限公司 一种骨髓间充质干细胞特异性启动元件在干细胞中的应用
US20220143099A1 (en) * 2019-04-02 2022-05-12 The General Hospital Corporation Methods to enhance t cell regeneration
CN111849905B (zh) * 2019-04-18 2023-03-24 上海交通大学 间充质干细胞靶向运输趋化因子和细胞因子的免疫疗法
CN111139222B (zh) * 2019-05-30 2020-12-29 北京双因生物科技有限公司 一种重组间充质干细胞及其制备方法和用途
EP4017512B1 (en) * 2019-08-23 2025-04-02 Orbsen Therapeutics Limited Compositions for monocyte and macrophage polarization and methods of use
WO2021194427A1 (en) * 2020-03-26 2021-09-30 Agency For Science, Technology And Research A method and system for introducing one or more exogenous substances into an immune cell
KR20230018378A (ko) * 2020-05-27 2023-02-07 유니버시타트 취리히 골수 세포 및 미세아교세포에서 치료 단백질을 특이적으로 발현하는 바이러스 벡터
EP4183872A4 (en) * 2020-07-16 2024-05-01 Shanghai Jiaotong University Immunotherapy method of targeted chemokine and cytokine delivery by mesenchymal stem cell
WO2022079322A1 (en) * 2020-10-16 2022-04-21 Fundació Centre De Regulació Genòmica Therapy for degenerative disease and tissue damage
CN114507643A (zh) * 2020-10-29 2022-05-17 未来智人再生医学研究院(广州)有限公司 一种表达il-2的多能干细胞衍生物及应用
CN114426953A (zh) * 2020-10-29 2022-05-03 未来智人再生医学研究院(广州)有限公司 一种表达il-12的多能干细胞衍生物及应用
CN114717232A (zh) * 2020-12-22 2022-07-08 未来智人再生医学研究院(广州)有限公司 表达irf-1靶向抑制因子的多能干细胞及其衍生物与应用
WO2023274355A1 (zh) * 2021-07-02 2023-01-05 上海交通大学 改造的间充质干细胞和免疫效应细胞联合治疗肿瘤
US20230137723A1 (en) * 2021-11-01 2023-05-04 MAM Holdings of West Florida, L.L.C. Mesenchymal stem cells for the prevention and targeted treatment of cancer and other disorders
CN114480413B (zh) * 2022-01-14 2022-11-04 北京贝来生物科技有限公司 一种活化肿瘤免疫应答的基因修饰干细胞制备方法
CN115463155B (zh) * 2022-11-01 2023-05-23 卡瑞济(北京)生命科技有限公司 间充质干细胞的用途
CN117503952B (zh) * 2022-11-24 2025-09-16 中国药科大学 一种基于血小板的免疫激活系统及其制备方法和应用
WO2024137869A2 (en) * 2022-12-20 2024-06-27 City Of Hope Stem cells for delivery of oncolytic viruses
US20250333700A1 (en) * 2024-02-28 2025-10-30 Gene Solutions Joint Stock Company Modified k562 feeder cell line expressing factors that enhance the activation and proliferation of natural killer cells and a method for its production

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040076622A1 (en) 2002-03-02 2004-04-22 Board Of Regents, The University Of Texas System Local production and/or delivery of anti-cancer agents by stromal cell precursors
CN1842339A (zh) * 2003-06-27 2006-10-04 株式会社雷诺再生医学研究所 含有间叶细胞作为有效成分、治疗脑神经疾病的体内给药治疗剂
JPWO2005007176A1 (ja) * 2003-06-27 2006-08-31 株式会社レノメディクス研究所 間葉系細胞を有効成分とする体内投与用脳神経疾患治療薬
US20050002904A1 (en) 2003-07-03 2005-01-06 Wary Kishore K. Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP)
JP5089389B2 (ja) * 2004-09-10 2012-12-05 コグネート セラピューティクス，インコーポレーテッド 移植における免疫応答の予防および治療のための肝臓間質細胞
EP1757703A3 (en) 2005-08-24 2007-12-05 Medizinische Hochschule Hannover Self-inactivating retroviral vector
CN103263439B (zh) * 2007-05-24 2015-04-22 埃普塞斯有限责任两合公司 Cd34干细胞相关方法和组合物
EP2019134A1 (en) 2007-07-26 2009-01-28 Vision 7 GmbH Gene therapy of chronic granulomatous disease
WO2011087637A1 (en) * 2009-12-08 2011-07-21 The Board Of Trustees Of The University Of Illinois Stem cell immune modulation methods of use and apparatus
US9434925B2 (en) * 2009-04-13 2016-09-06 Apceth Gmbh & Co. Kg Genetically modified mesenchymal stem cell that express an exogenous cytotoxic protein
CN101974485A (zh) * 2010-11-12 2011-02-16 苏州大学 具有最佳迁移能力的间充质干细胞的制备方法及其应用
US9101597B2 (en) 2013-03-14 2015-08-11 The Administration Of The Tulane Educational Fund Immunoprotective primary mesenchymal stem cells and methods
WO2015035235A1 (en) * 2013-09-06 2015-03-12 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) Compositions and methods for increasing mesenchymal stromal cell migration to tumors
EP4303229A3 (en) * 2014-01-21 2024-04-17 Novartis AG Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
WO2016146819A1 (en) * 2015-03-18 2016-09-22 Apceth Gmbh & Co. Kg Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells

Also Published As

Publication number Publication date
CA2956987A1 (en) 2016-02-25
US20200268802A1 (en) 2020-08-27
US20170239297A1 (en) 2017-08-24
EP3656387A2 (en) 2020-05-27
CA2956987C (en) 2023-03-21
JP2017525364A (ja) 2017-09-07
IL250388A0 (en) 2017-03-30
AU2015306231B2 (en) 2019-11-21
US11464806B2 (en) 2022-10-11
EP3656387A3 (en) 2020-07-01
CN106659742B (zh) 2021-09-03
WO2016026854A3 (en) 2016-04-14
CN106659742A (zh) 2017-05-10
EP3182984B1 (en) 2019-10-30
IL250388B (en) 2021-02-28
WO2016026854A2 (en) 2016-02-25
EP3182984A2 (en) 2017-06-28
AU2015306231A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
JP6712993B2 (ja) 免疫細胞を惹起及び／又は活性化するための免疫応答刺激性サイトカインを発現する遺伝子改変型間葉系幹細胞
US20220378842A1 (en) Combinatorial cancer immunotherapy
JP6971986B2 (ja) 免疫療法の抗腫瘍活性を高めるための間葉系幹細胞
WO2018191619A1 (en) Combinatorial cancer immunotherapy
WO2016146819A1 (en) Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells
US11419898B2 (en) Combinatorial cancer immunotherapy
US20230312671A1 (en) Grp78 targeted adoptive cell therapy
JP2019170176A (ja) ケモカインレセプターと細胞接着分子を発現するｃｄ３陰性細胞の集団、およびその利用
KR20230018378A (ko) 골수 세포 및 미세아교세포에서 치료 단백질을 특이적으로 발현하는 바이러스 벡터
WO2021085497A1 (ja) がんを治療するための医薬、組み合わせ医薬、医薬組成物、免疫応答性細胞、核酸送達媒体、及び製品
JP2024170618A (ja) Ｎｋ細胞の活性化及び増幅のために遺伝的に操作された細胞株、及びその用途
CN113383069B (zh) 使用转化的t细胞培养脐带血来源的自然杀伤细胞的方法
EP3068875A1 (en) Post-natal hematopoeitic endothelial cells and their isolation and use
JP7477120B2 (ja) Ｎｋ細胞の活性化及び増幅のために遺伝的に操作された細胞株、及びその用途
HK1233546A1 (en) Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
HK1233546B (en) Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
US12453763B2 (en) Human vaccine compositions and methods for treating leukemia
WO2025166096A1 (en) Method of induction of immune cells into a memory-like state
HK40057204A (zh) 组合癌症免疫疗法
Day Granulocyte-Colony Stimulating Factor Reprograms the Bone Marrow Microenvironment to Suppress B Lymphopoiesis
Class et al. Patent application title: Development Of Natural Killer Cells And Functional Natural Killer Cell Lines Inventors: Schickwann Tsai (Salt Lake City, UT, US)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200512

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200602

R150 Certificate of patent or registration of utility model

Ref document number: 6712993

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250